In October 2009, the National Institute for Health and Clinical Excellence (NICE) issued guidance on the use of ▼prasugrel (Efient) in patients with acute coronary syndrome undergoing percutaneous coronary intervention.1 This recommended prasugrel as a better option than clopidogrel in, for example, patients with ST-segment-elevation myocardial infarction or diabetes mellitus. Evidence of prasugrel's efficacy was based on one trial comparing it with …